Immunotherapy for COVID-19
Citation: AminJafari A, Ghasemi S. The possible of immunotherapy for COVID-19: A systematic review. International Immunopharmacology 2020; 83: 106455
What is this? Immunotherapy has been suggested as a treatment for COVID-19.
In this rapid systematic review, the authors searched for articles on the effects of immunotherapy (e.g. monoclonal antibody, interleukins, vaccines) for the three coronaviruses SARS-CoV, MERS-CoV and SARS-CoV-2, which mentioned the potential relevance to COVID-19. They restricted their search to studies published in English and did the search up to 24 March 2020. They included 7 articles.
What was found: At the time of the review, the available research was insufficient to determine the effects of immunotherapy for treating patients with COVID-19.
Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence on the coronavirus (COVID-19) but may not have the time, initially, to read the original report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence that is presented within it is relevant to their decision-making they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions. Evidence Aid cannot be held responsible for any decisions made about the coronavirus (COVID-19) on the basis of this summary alone.
If you have found this summary helpful, please consider making a donation. If everyone who looked at our COVID-19 resources gave us just £2 per month, it would fund Evidence Aid’s life-saving work.